News - Part 3

CanFite’s Piclidenoson Positioned For Successful Phase 3 in Psoriasis

Can-Fite BioPharma Ltd. (NYSEMKT: CANF) announced on November 1, 2016, that the company reached an agreement with the European Medicines Agency (EMA) on the final design of a global pivotal Phase 3 trial for its lead drug candidate, piclidenoson (formerly CF101), in the treatment of psoriasis. Can-Fite intends to initiate the Phase 3 trial in the…

ASH Abstract Confirms Positive Outlook For Actinium’s Actimab-A

Last week, the American Society of Hematology (ASH) released abstracts for the upcoming 58th Annual Meeting & Exposition to be held December 3-6, 2016 in San Diego, CA. Included as part of the release was abstract #4050 from Actinium Pharmaceuticals, Inc. (NYSEMKT: ATNM). The abstract highlights the company’s Phase 1 clinical results with Actimab-A for the…

Valeritas V-Go Saves Money, Improves Quality of Life

Valeritas Holdings, Inc. (VLRX) is a commercial-stage medical device company focused on developing innovative technologies to improve the health and quality of life for people with Type 2 diabetes. The company’s flagship product is called V-Go, and it is currently on the market in the U.S. V-Go is a small, wearable device designed for patients…

Could VistaGen’s AV101 Be The Next Abilify?

I’ve been following VistaGen Therapeutics (NASDAQ: VTGN) for several months now. The California-based biotech is developing AV101, a glycine B (GlyB) receptor antagonist that negatively modulates the N-Methyl-D-aspartic acid (NMDA) receptor. AV-101 is an oral prodrug candidate that has demonstrated impressive antidepressant effects and safety in preclinical and Phase 1 studies. The mechanism of action…

Comparing Actinium’s Actimab-A To Seattle Genetics’ SGN-CD33A

Last month, Actinium Pharmaceuticals Inc. (NYSEMKT: ATNM) announced the initiation of a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia (AML) who are over the age of 60. Elderly patients with AML face poor prognosis and have limited viable treatment options. it is an area of significant unmet medical…

An Interview With Relmada Therapeutics

Relmada Therapeutics (OTC: RLMD) is developing REL-1017 for the treatment of depression and neuropathic pain. REL-1017, also known as dextromethadone or d-methadone, is a non-competitive antagonist of the N-methyl-D-aspartic acid (NMDA) receptor. This mechanism of action has received significant attention from the psychiatric community over the past several years due to the expected rapid onset…

Can-Fite An Emerging NASH Play With CF102

Last week, Allergan plc (AGN) acquired two companies on the same day, both in an effort to strengthen its focus on NASH. Allergan spent $615 million to acquire Tobira Therapeutics, Inc. (TBRA) and $50 million to acquire privately-held Akarna Therapeutics. The acquisition of Tobira gives Allergan cenicriviroc, an oral Phase 3 ready potent inhibitor of the…

Here’s Why Revive Will Close The Valuation Gap With Peers

Revive Therapeutics (TSXV: RVV) (RVVTF) Looks Significant Undervalued Valuing small and micro-cap biopharma companies is a difficult task. Most have no revenues, let alone earnings where valuation multiples can be applied. And even when revenues or earnings do exist, the market can be fickle on what specific multiples to apply. Discounted cash flow seems to be…

MabVax Phase 1 Trial With HuMab-5B1 Progressing Nicely

On September 19, 2016, MabVax Therapeutics, Inc (NASDAQ: MBVX) provided a brief update on the ongoing Phase 1 clinical trial testing the safety and tolerability of MVT-5873 as a monotherapy and with chemotherapy in subjects with advanced prostate cancer. MVT-5873 is the company’s fully human monoclonal antibody, HuMab-5B1, that targets the tetrasaccharide carbohydrate moiety sLeA…

What’s Next For BrainStorm Cell Therapeutics

In July 2016, BrainStorm Cell Therapeutics (NASDAQ: BCLI) reported top-line data from a Phase 2 multi-center study with NurOwn® for the treatment of ALS. The company is currently in the process of finalizing the full data analysis from this trial and plans to submit the results for presentation at a medical conference during the first…